New treatment options for the management of non-Hodgkin lymphoma

Abstract

Although the outcome of patients with non-Hodgkin lymphoma (NHL) has, in general, improved signifi cantly over years, treatment failure due to drug resistance remains a problem. Recently, the focus of drug development has shifted from conventional cytotoxic drugs to agents directed against specifi c molecular targets and immunotherapy. Th is has mainly been driven by advances in the understanding of the molecular pathogenesis of NHL. A large number of promising new agents are in preclinical and clinical development. Th e challenge for clinicians is how best to incorporate them into already existing treatment regimes. Th is review will highlight some recent clinical trials focussing on targeted small molecules and monoclonal antibodies in NHL.

The Best is yet to come – New drugs in Haematology

“…Edrecolomab Today, on the contrary, clinicians are faced with a real deluge of -mabs and -mibs diffi cult to keep in focus even for the experienced expert. In this situation MEMO could fortunately motivate some leading international specialists to give us concise and thoughtful reviews of new drugs to be expected soon to enter every day clinical care in the fi elds of AML [9], ALL [10], NHL [11] and CMPDs [12]. From this series of articles we can easily approximate further clinically meaningful progress in all these entities in the near future.…”